[Form 4] Inozyme Pharma, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Form 4 Overview – Inozyme Pharma, Inc. (INZY)

This Form 4 discloses that Robert L. Hopfner, a director of Inozyme Pharma and managing partner of Pivotal bioVenture Partners, disposed of his indirect holdings in the company on 1 July 2025 as a result of Inozyme’s acquisition by BioMarin Pharmaceutical Inc.

• Transaction structure: The shares were tendered pursuant to the Agreement and Plan of Merger dated 16 May 2025 between Inozyme, BioMarin and Incline Merger Sub.
• Consideration: All common shares were exchanged for $4.00 cash per share (the “Merger Consideration”), without interest and subject to tax withholding.
• Holdings affected:
  • Pivotal bioVenture Partners Fund I, L.P. – 2,923,110 shares
  • Pivotal bioVenture Partners Fund II, L.P. – 1,571,741 shares
  Total indirect disposition: 4,494,851 shares.
• Post-merger status: Effective 1 July 2025, Incline Merger Sub merged with and into Inozyme, making Inozyme a wholly-owned subsidiary of BioMarin.

No derivative securities were reported. The filing is made by one reporting person and executed by power of attorney.

Insights

M&A Specialist

TL;DR: Filing shows cash-out of 4.5 M shares at $4 via BioMarin merger; confirms deal close and shareholder liquidity.

The Form 4 is strictly confirmatory: it documents the automatic tender of Pivotal-controlled shares when BioMarin’s offer became effective. The $4.00 per-share price, already agreed in May, is now consummated, demonstrating completion of the acquisition and extinguishment of public equity. For investors, the key takeaway is that all public shareholders—including large VC holders—have received the same cash consideration, closing the transaction. There is no new valuation information beyond the stated consideration, but the filing eliminates any residual execution risk surrounding the merger.

Portfolio Manager

TL;DR: Insider filing confirms exit; INZY no longer an independent investable equity post 1 July 2025.

From a portfolio perspective, the event converts equity exposure to cash at $4.00 per share. Investors holding INZY should already have been tendered or will receive cash shortly; the stock will be delisted or stopped trading. There is no incremental upside or downside signalled here—only confirmation that the liquidity event closed. Any residual positions in trading systems should be reconciled and removed.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hopfner Robert Lorne

(Last) (First) (Middle)

C/O INOZYME PHARMA, INC.

321 SUMMER STREET SUITE 400

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Inozyme Pharma, Inc. [ INZY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/01/2025		U(1)		2,923,110(2)	D	$4	0	I	By Pivotal(3)(4)(5)
Common Stock	07/01/2025		U(1)		1,571,741(2)	D	$4	0	I	By Pivotal(4)(5)(6)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 16, 2025, by and among the Issuer, BioMarin Pharmaceutical Inc., a Delaware corporation ("Parent"), and Incline Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $4.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of July 1, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly-owned subsidiary of Parent (the "Merger").

2. Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each share of Company Common Stock held by the Reporting Person was tendered in exchange for the Merger Consideration, without interest and subject to any withholding of taxes required by applicable law.

3. Held directly by Pivotal bioVenture Partners Fund I, L.P.

4. The general partner of Pivotal bioVenture Partners Fund I, L.P and Pivotal bioVenture Partners Fund II, L.P. (collectively, "Pivotal") is Pivotal bioVenture Partners Fund I G.P., L.P. ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd (the "Ultimate General Partner").

5. Pivotal Partners is wholly owned by Pivotal Life Sciences Holdings Limited ("Pivotal Life Sciences"). Pivotal Life Sciences is wholly owned by Nan Fung Life Sciences Holdings Limited ("Nan Fung Life Sciences"), and Nan Fung Life Sciences is wholly owned by NF Investment Holdings LImited ("NFIHL"), which is wholly owned by Nan Fung Group Holdings Limited ("NFGHL"). The members of the Executive Committee of NFGHL make investment decisions with respect to the securities of the Issuer held by Pivotal. Mr. Kam Chung Leung, Mr. Frank Kai Shui Seto, Mr. Vincent Sai Sing Cheung, Mr. Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao and Mr. Chun Wai Nelson Tang are the members of the Executive Committee of NFGHL. Robert Hopfner, a managing partner of the Ultimate General Partner, is a member of the board of directors of the Issuer. Such persons and entities disclaim beneficial ownership over such securities except to the extent of any pecuniary interest therein.

6. Held directly by Pivotal bioVenture Partners Fund II, L.P.

	/s/ Sanjay Subramanian, as attorney-in-fact for Robert Hopfner	07/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.